Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib + SHR-1701 for EGFR-mutant recurrent or advanced non-small cell lung cancer
CTR20222033Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Sep 2022
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa and almonertinib in non-small cell lung cancer (NSCLC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Primary endpoints: Dose-limiting toxicity, Grade 3 or higher treatment-related adverse events and serious treatment-related serious adverse events and 1 more. Started Sep 2022; status: active.
02
Drugs
retlirafusp alfaalmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222033.